Aethlon Advances in Cancer Study, Cuts Costs

Aethlon Medical has reached a significant milestone in its Australian cancer study by entering the third and final dosing phase, marking progress in their research on the Hemopurifier, a device aimed at treating cancer and viral infections. They've also expanded their intellectual property, with new patents covering potential applications for long COVID, and made strides in preclinical research into other diseases like rheumatoid arthritis and chronic kidney disease. Financially, the company reduced its operating expenses by nearly 22%, reflecting strong cost management. What does it mean for you? Aethlon's advancements suggest potential future treatments for cancer and viral infections, possibly improving options for patients with unmet medical needs. Meanwhile, their financial discipline indicates a stable footing, which is promising for ongoing and future projects.